NEW YORK – Zeus Scientific announced on Friday that it has acquired exclusive worldwide rights to synthetic peptides from Sheba Medical Center's technology transfer company Tel Hashomer Medical Research, Infrastructure and Services.
Financial and other terms of the deal were not disclosed.
Some of the peptides comprise a plurality of epitopes derived from different proteins, while others comprise a plurality of citrullinated residues, Zeus said in a statement. The Branchburg, New Jersey-based infectious disease and autoimmune disorder diagnostic company said it intends to use the peptides to develop a new generation of immunoassays that will measure autoantibodies to help diagnose rheumatoid arthritis.
Zeus currently offers a variety of immunoassays, including Lyme disease tests cleared by the US Food and Drug Administration and antibody tests for SARS-CoV-2.